VARIAN MED SYS INC's ticker is VAR and the CUSIP is 92220P105. A total of 577 filers reported holding VARIAN MED SYS INC in Q4 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
About VARIAN MED SYS INC
Varian Medical Systems Inc. is a leading manufacturer of medical devices and software for treating cancer and other medical conditions. The company has been in business for over 70 years and has a strong reputation for innovation and quality.
Varian's products include radiation therapy systems, software for managing cancer treatment, and other medical devices. The company's products are used by hospitals and clinics around the world to treat cancer patients.
One of the key strengths of Varian is its focus on research and development. The company invests heavily in R&D to develop new products and improve existing ones. This has helped Varian stay ahead of its competitors and maintain its position as a leader in the medical device industry.
Another strength of Varian is its strong financial position. The company has a solid balance sheet and generates strong cash flows. This has allowed Varian to invest in R&D and make strategic acquisitions to expand its product portfolio.
Despite these strengths, Varian faces some challenges. The medical device industry is highly competitive, and Varian must continue to innovate to stay ahead of its competitors. In addition, the company is exposed to regulatory risks, as changes in regulations could impact its ability to sell its products.
Overall, Varian Medical Systems Inc. is a strong company with a solid reputation in the medical device industry. Its focus on innovation and strong financial position make it a good investment for long-term investors.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $14,074,000 | +6.5% | 79,727 | +5.6% | 0.00% | 0.0% |
Q4 2020 | $13,217,000 | -80.1% | 75,519 | -80.4% | 0.00% | -85.7% |
Q3 2020 | $66,407,000 | -81.1% | 386,091 | -86.5% | 0.01% | -82.1% |
Q2 2020 | $350,940,000 | +61.5% | 2,864,346 | +35.4% | 0.08% | +36.8% |
Q1 2020 | $217,251,000 | -30.2% | 2,116,216 | -3.4% | 0.06% | -12.3% |
Q4 2019 | $311,048,000 | +17.5% | 2,190,325 | -1.5% | 0.06% | +8.3% |
Q3 2019 | $264,818,000 | +6.1% | 2,223,683 | +21.2% | 0.06% | +9.1% |
Q2 2019 | $249,700,000 | -4.5% | 1,834,279 | -0.6% | 0.06% | -6.8% |
Q1 2019 | $261,476,000 | +20.9% | 1,845,016 | -3.3% | 0.06% | +9.3% |
Q4 2018 | $216,226,000 | +0.1% | 1,908,262 | -1.1% | 0.05% | +20.0% |
Q3 2018 | $215,984,000 | +5.2% | 1,929,629 | +6.9% | 0.04% | -2.2% |
Q2 2018 | $205,269,000 | -2.3% | 1,805,039 | +5.3% | 0.05% | -4.2% |
Q1 2018 | $210,189,000 | +12.7% | 1,713,724 | +2.2% | 0.05% | +17.1% |
Q4 2017 | $186,429,000 | +14.4% | 1,677,274 | +3.0% | 0.04% | +10.8% |
Q3 2017 | $163,009,000 | +1.9% | 1,629,110 | +5.1% | 0.04% | -2.6% |
Q2 2017 | $159,921,000 | -0.1% | 1,549,762 | -11.8% | 0.04% | -2.6% |
Q1 2017 | $160,054,000 | +5.1% | 1,756,329 | +3.6% | 0.04% | +2.6% |
Q4 2016 | $152,239,000 | -18.4% | 1,695,684 | -9.6% | 0.04% | -19.1% |
Q3 2016 | $186,624,000 | +72.3% | 1,875,046 | +42.3% | 0.05% | +67.9% |
Q2 2016 | $108,334,000 | -8.1% | 1,317,460 | -10.6% | 0.03% | -9.7% |
Q1 2016 | $117,867,000 | +1.2% | 1,472,955 | +2.2% | 0.03% | +3.3% |
Q4 2015 | $116,471,000 | +8.2% | 1,441,468 | -1.2% | 0.03% | 0.0% |
Q3 2015 | $107,684,000 | -33.8% | 1,459,534 | -24.3% | 0.03% | -28.6% |
Q2 2015 | $162,542,000 | -13.7% | 1,927,444 | -3.7% | 0.04% | -12.5% |
Q1 2015 | $188,320,000 | +10140.3% | 2,001,483 | +9317.4% | 0.05% | – |
Q4 2014 | $1,839,000 | +18.4% | 21,253 | +9.6% | 0.00% | – |
Q3 2014 | $1,553,000 | -2.6% | 19,386 | +1.0% | 0.00% | – |
Q2 2014 | $1,595,000 | -85.7% | 19,185 | -85.6% | 0.00% | -100.0% |
Q1 2014 | $11,169,000 | +1310.2% | 132,980 | +1203.9% | 0.00% | – |
Q4 2013 | $792,000 | +64.3% | 10,199 | +58.0% | 0.00% | – |
Q3 2013 | $482,000 | -80.0% | 6,455 | -81.9% | 0.00% | -100.0% |
Q2 2013 | $2,405,000 | – | 35,651 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ownership Capital B.V. | 807,989 | $89,808,000 | 6.28% |
LaFleur & Godfrey LLC | 125,849 | $13,988,000 | 3.44% |
Saratoga Research & Investment Management | 420,832 | $46,775,000 | 3.27% |
CAPITAL COUNSEL LLC/NY | 322,779 | $35,877,000 | 2.95% |
Fairpointe Capital LLC | 1,196,083 | $132,945,000 | 2.51% |
OAKBROOK INVESTMENTS LLC | 323,648 | $35,973,000 | 2.28% |
North Growth Management Ltd. | 78,000 | $8,720,000 | 2.28% |
Alecta Tjanstepension Omsesidigt | 2,464,000 | $273,948,000 | 2.22% |
SPEECE THORSON CAPITAL GROUP INC | 100,246 | $11,142,000 | 2.21% |
JLB & ASSOCIATES INC | 82,081 | $9,123,000 | 1.98% |